Notice of Annual General Meeting 2025
Telix announces its Annual General Meeting of shareholders to be held at
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
Telix today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study.
Telix Responds to Recent U.S. Government Actions
Telix advises that it does not expect any material impact on its business or supply chain as the result of the international trade tariffs levied by the U.S. government, announced on 2 April 2025.
Anne Whitaker Appointed as Non-Executive Director
Telix today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 2025
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
Telixtoday announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s next-generation PSMA-PET imaging[1] agent for prostate cancer.
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
Telix today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or ‘ANVISA’) has approved Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) the Company’s lead prostate cancer imaging agent. Illuccix® is the first and only PSMA-PET[1] prostate cancer imaging agent to receive full regulatory approval in Brazil.
Telix Completes Acquisition of FAP-targeting Theranostic Candidates
Telix today announces that it has completed the transaction to expand its theranostic pipeline with new candidates targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nuclear medicine.
Patients Risk Missing Out on Revolution in Cancer Treatment: Report
Tens of thousands of Australians risk missing out on a new era of cancer treatment if Australia fails to fund and build the medical infrastructure needed to support it, according to a landmark new report by Telix.
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
Telix invites investors to join a webinar showcasing the Company’s late-stage and next-generation radiotherapeutic candidates in urologic oncology.
In this education session, Telix and global key opinion leaders will provide an overview on the development of its therapeutic candidates in prostate and kidney cancers.
FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its breakthrough investigational kidney cancer PET imaging agent TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab), granted a Priority Review and provided a PDUFA date of 27 August 2025, paving the way for a U.S. commercial launch in 2025.